APA aipamena

Hill, L. F., Clements, M. N., Turner, M. A., Donà, D., Lutsar, I., Jacqz-Aigrain, E., . . . Sharland, M. (2022). Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): A multicentre, randomised, open-label, phase 2b, non-inferiority trial. Lancet Child Adolesc Health.

Chicago Style aipamena

Hill, Louise F., et al. "Optimised Versus Standard Dosing of Vancomycin in Infants With Gram-positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-label, Phase 2b, Non-inferiority Trial." Lancet Child Adolesc Health 2022.

MLA aipamena

Hill, Louise F., et al. "Optimised Versus Standard Dosing of Vancomycin in Infants With Gram-positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-label, Phase 2b, Non-inferiority Trial." Lancet Child Adolesc Health 2022.